Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study

Journal of the American College of Cardiology

Volumn 29, Issue 2, 1997, Pages 229-236

  Vantrimpont, Pascal ^a   Rouleau, Jean L ^a   Wun, Chuan Chuan ^b   Ciampi, Antonio ^a   Klein, Marc ^c   Sussex, Bruce ^d   Arnold, J Malcolm O ^e   Moyé, Lemuel ^b   Pfeffer, Marc ^f  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUROTRANSMITTER AGENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031033495     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00489-5     Document Type: Article

References (24)

1. Pfeffer MA, Braunwald E, Moyé LA, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
2. Rouleau JL, de Champlain J, Klein M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993;22:390-8.
3. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
4. Rogers WJ, Bowlby LJ, Chandra NC, et al, for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-14.
5. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-32.
6. Gundersen T. Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction. Br Heart J 1983; 50:135-9.
7. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.
8. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16.
9. Held P. Effects of beta blockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects. Am J Cardiol 1993;71:39C-44C.
10. Lichstein E, Hager WD, Gregory JJ, Fleiss JL, Rolnitzky LM, Bigger JT Jr, for the Multicenter Diltiazem Post-Infarction Research Group. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol 1990;16:1327-32.
11. Rouleau JL, Packer M, Moyé L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583-91.
12. Moyé LA, Pfeffer MA, Braunwald E, for the SAVE Investigators. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. Am J Cardiol 1991;68:70D-9D.
13. Mettauer B, Rouleau JL, Bichet D, et al. Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. Circulation 1986;73:492-502.
14. Wilson N, Ledsome JR, Keeler R, Rankin AJ, Wade JP, Cournyea CA. Heterologous radioimmunoassay of atrial natriuretic peptide in dog and rabbit plasma. J Immunoassay 1986;7:73-96.
15. Nelesen RA, Dimsdale JE, Ziegler MG. Plasma atrial natriuretic peptide is unstable under most storage conditions. Circulation 1992;86:463-6.
16. Gunnar RM, Bourdillon PDV, Dixon DW, et al. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular procedures. J Am Coll Cardiol 1990;16:249-92.
17. Omland T, Bonarjee VVS, Lie RT, Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am J Cardiol 1995;76:230-5.
18. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
19. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
20. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87 Suppl VI:VI-40-8.
21. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993;88:136-45.
22. Sigurdsson A, Swedberg K, Ullman B. Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure. Eur Heart J 1994;15:247-54.
23. St. John Sutton M, Pfeffer MA, Plappert T, et al., for the SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation 1994;89:68-75.
24. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.